MGC Pharmaceuticals Limited GM Statement (1560U)

TIDMMXC

RNS Number : 1560U

MGC Pharmaceuticals Limited

31 March 2021

 
 31 March 2021                                       Results of General Meeting 
   ASX Code: 
      MXC 
   LSE Code: 
      MXC 
 
                                        MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the 
                                     Company'), would like to confirm the results of the Company's 
                                        General Meeting held 31 March 2021. All resolutions put 
                                                 to the meeting were passed on a poll. 
                                        Details of the proxy and poll voting on the resolutions 
                                                  are set out in the attached report. 
                                 http://www.rns-pdf.londonstockexchange.com/rns/1560U_1-2021-3-31.pdf 
                                                               --Ends-- 
                                      Authorised for issue by Narelle Warren, Company Secretary, 
                   further information, please contact: PR/IR Advisors - Media &             MGC Pharmaceuticals Ltd 
                                             Capital Partners                     Roby Zomer 
                                      Rod Hinchcliffe (IR) +61             CEO & Managing Director 
                                          412 277 377                          +61 8 6382 3390 
                                       Rod.Hinchcliffe@mcpartners.com.au    info@mgcpharma.com.au 
                                    UK Broker - Turner Pope              UK PR Advisors - Tavistock 
                                     Andy Thacker                         Charles Vivian +44 207 920 
                                                Andy.Thacker@TurnerPope.com          3150 
                                   Zoe Alexander +44 20 3657            Charles.Vivian@tavistock.co.uk 
                                      0050                                 Tim Pearson +44 7983118 
                                                Zoe.Alexander@TurnerPope.com         502 
                                                                         Tim.Pearson@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

GMSDKDBQDBKDFNN

(END) Dow Jones Newswires

March 31, 2021 07:54 ET (11:54 GMT)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Oct 2024 to Nov 2024